Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics


Lexicon Pharmaceuticals, Inc. (LXRX)

Today's Latest Price: $1.94 USD

0.07 (-3.48%)

Updated Jul 2 4:00pm

Add LXRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

LXRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for LXRX is 5.86 -- better than 92.6% of US stocks.
  • LXRX's current price/earnings ratio is 2.5, which is higher than merely 2.65% of US stocks with positive earnings.
  • As for revenue growth, note that LXRX's revenue has grown 579.52% over the past 12 months; that beats the revenue growth of 98.86% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Lexicon Pharmaceuticals Inc are ALBO, TNAV, MEET, FOLD, and PULM.
  • Visit LXRX's SEC page to see the company's official filings. To visit the company's web site, go to www.lexpharma.com.
LXRX Daily Price Range
LXRX 52-Week Price Range

LXRX Stock Price Chart Technical Analysis Charts


LXRX Price/Volume Stats

Current price $1.94 52-week high $6.49
Prev. close $2.01 52-week low $1.13
Day low $1.93 Volume 547,079
Day high $2.03 Avg. volume 950,355
50-day MA $1.97 Dividend yield N/A
200-day MA $2.94 Market Cap 207.52M

Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio


Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.

LXRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$1.94$7.85287%

We started the process of determining a valid price forecast for Lexicon Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Lexicon Pharmaceuticals Inc ranked in the 75th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 288.67% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Lexicon Pharmaceuticals Inc, consider:

  • In the past 4.13 years, Lexicon Pharmaceuticals Inc has a compound free cash flow growth rate of -0.1%; that's better than only 10.17% of cash flow producing equities in the Healthcare sector, where it is classified.
  • Lexicon Pharmaceuticals Inc's weighted average cost of capital (WACC) is 6%; for context, that number is higher than merely 3.78% of tickers in our DCF set.
  • Lexicon Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%279%
1%283%
2%287%
3%291%
4%294%
5%298%

Want more companies with a valuation profile/forecast similar to that of Lexicon Pharmaceuticals Inc? See AMEH, MYL, ABC, CVS, and HZNP.


LXRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

LXRX Latest Social Stream


Loading social stream, please wait...

View Full LXRX Social Stream

Latest LXRX News From Around the Web

Below are the latest news stories about Lexicon Pharmaceuticals Inc that investors may wish to consider to help them evaluate LXRX as an investment opportunity.

Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions

THE WOODLANDS, Texas, June 13, 2020 --  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for ZynquistaTM (sotagliflozin) at the virtual 80th American.

Yahoo | June 13, 2020

Edited Transcript of LXRX earnings conference call or presentation 27-Apr-20 12:00pm GMT

Q1 2020 Lexicon Pharmaceuticals Inc Earnings Call

Yahoo | June 11, 2020

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

The audio webcast for this conference will be available in the “Events” section of the Lexicon website at www.lexpharma.com/. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to its first commercial product, XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in diabetes and metabolism, oncology and neuropathic pain.

Yahoo | May 27, 2020

Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines

Lexicon Pharmaceuticals, Inc. (LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the American Society of Clinical Oncology (ASCO) 2020 annual meeting (May 29 - June 2, 2020). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.

Yahoo | May 13, 2020

Lexicon Pharmaceuticals (NASDAQ: LXRX) Q1 2020 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Q1 2020 earnings call dated Apr. 27, 2020 Corporate Participants: Kimberly Lee — Head of Investor Relations and Corporate Strategy Lonnel Coats — President and Chief Executive Officer and Director Pablo Lapuerta — Executive Vice President and Chief Medical Officer Jeffrey L. Wade — Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer Presentation: Operator Ladies and gentlemen, […]

news.alphastreet.com | April 27, 2020

Read More 'LXRX' Stories Here

LXRX Price Returns

1-mo 2.65%
3-mo 10.23%
6-mo -51.01%
1-year -69.16%
3-year -88.29%
5-year -77.62%
YTD -53.25%
2019 -37.50%
2018 -32.79%
2017 -28.56%
2016 3.91%
2015 108.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8634 seconds.